Evaluation of Vav3.1 as prognostic marker in endometrial cancer
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
Grantová podpora
J-3807
Austrian Science Fund
PubMed
30083818
PubMed Central
PMC6153599
DOI
10.1007/s00432-018-2725-2
PII: 10.1007/s00432-018-2725-2
Knihovny.cz E-zdroje
- Klíčová slova
- Cancer, Endometrial cancer, Guanine nucleotide exchange factor, Protein isoform, Transcript variant, Vav3,
- MeSH
- adenokarcinom z jasných buněk genetika patologie terapie MeSH
- dospělí MeSH
- kombinovaná terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- nádorové biomarkery genetika MeSH
- nádory endometria genetika patologie terapie MeSH
- následné studie MeSH
- prognóza MeSH
- protein - isoformy MeSH
- protoonkogenní proteiny c-vav genetika MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- serózní cystadenokarcinom genetika patologie terapie MeSH
- studie případů a kontrol MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- nádorové biomarkery MeSH
- protein - isoformy MeSH
- protoonkogenní proteiny c-vav MeSH
- VAV3 protein, human MeSH Prohlížeč
PURPOSE: Vav3 is a guanine nucleotide exchange factor that regulates the activity of Rho/Rac family GTPases. In a study on ovarian cancer, we recently demonstrated pronounced prognostic and predictive value of Vav3.1, a specific truncation variant of the parental Vav3 gene. Here, we sought to investigate the role of Vav3.1 in the most prevalent gynecological tumor entity, endometrial cancer. METHODS: Vav3.1 transcript levels were determined in a large cohort of endometrial cancer patients using variant-specific PCR (n = 239), and non-malignant endometrial tissue served as control (n = 26). Expression levels of Vav3.1 were stratified according to established clinicopathological characteristics and correlated to long-term patient survival (average follow-up of > 7.5 years). Type 1 and type 2 cancers were separately investigated. RESULTS: While Vav3.1 was markedly overexpressed in endometrial cancer tissue, we could not detect associations with clinical parameters related to prognosis, such as FIGO stage and tumor grade. Kaplan-Meier estimators of different measures of survival failed to show prognostic significance of Vav3.1 in endometrial cancer. Lack of prognostic value was observed for both type 1 and type 2 cancers. CONCLUSIONS: Our study shows that Vav3.1 is not suited as a marker of cancer progression and/or treatment response in endometrial cancer. Feasibility and potential benefit of targeting Vav3.1 in endometrial cancer needs to be evaluated in future studies, proceeding from its clear, roughly ten-fold, induction in the malignant endometrium.
Internal Medicine 5 Medical University of Innsbruck 6020 Innsbruck Austria
Lungenzentrum Kantonsspital St Gallen Rorschacherstrasse 95 9007 St Gallen Switzerland
Medical Clinic 3 Oncology Hematology and Rheumatology University Clinic Bonn 53127 Bonn Germany
Oncotyrol Center for Personalized Cancer Medicine GmbH 6020 Innsbruck Austria
Zobrazit více v PubMed
Aguilar H, et al. VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Res: BCR. 2014;16:R53. doi: 10.1186/bcr3664. PubMed DOI PMC
Boesch M, et al. The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem. Cell Char Oncotarget. 2014;5:7027–7039. PubMed PMC
Boesch M, Zeimet AG, Rumpold H, Gastl G, Sopper S, Wolf D. Drug transporter-mediated protection of cancer stem cells from ionophore antibiotics. Stem Cells Transl Med. 2015 doi: 10.5966/sctm.2015-0054. PubMed DOI PMC
Boesch M, Sopper S, Wolf D. Ionophore antibiotics as cancer stem cell-selective drugs: open questions. Oncologist. 2016 doi: 10.1634/theoncologist.2016-0159. PubMed DOI PMC
Boesch M, Sopper S, Zeimet AG, Reimer D, Gastl G, Ludewig B, Wolf D. Heterogeneity of cancer stem cells: rationale for targeting the stem cell niche biochimica. Et Biophysica Acta. 2016;1866:276–289. doi: 10.1016/j.bbcan.2016.10.003. PubMed DOI PMC
Boesch Maximilian, Reimer Daniel, Sopper Sieghart, Wolf Dominik, Zeimet Alain G. (Iso‐)form Matters: Differential Implication of Vav3 Variants in Ovarian Cancer. The Oncologist. 2018;23(7):757–759. doi: 10.1634/theoncologist.2017-0683. PubMed DOI PMC
Brantley-Sieders DM, Zhuang G, Vaught D, Freeman T, Hwang Y, Hicks D, Chen J. Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo molecular cancer research. MCR. 2009;7:615–623. doi: 10.1158/1541-7786.MCR-08-0401. PubMed DOI PMC
Bustelo XR. Regulatory and signaling properties of the Vav family. Mol Cell Biol. 2000;20:1461–1477. doi: 10.1128/MCB.20.5.1461-1477.2000. PubMed DOI PMC
Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–2529. doi: 10.1056/NEJMra041842. PubMed DOI
Carvalho MJ, Laranjo M, Abrantes AM, Torgal I, Botelho MF, Oliveira CF. Clinical translation for endometrial cancer stem cells hypothesis. Cancer Metastasis Rev. 2015;34:401–416. doi: 10.1007/s10555-015-9574-0. PubMed DOI
Chan RW, Schwab KE, Gargett CE. Clonogenicity of human endometrial epithelial and stromal cells. Biol Reprod. 2004;70:1738–1750. doi: 10.1095/biolreprod.103.024109. PubMed DOI
Friel AM, et al. Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. Cell Cycle. 2008;7:242–249. doi: 10.4161/cc.7.2.5207. PubMed DOI
Gargett CE, Masuda H. Adult stem cells in the endometrium. Mol Hum Reprod. 2010;16:818–834. doi: 10.1093/molehr/gaq061. PubMed DOI
Gotte M, et al. The adult stem cell marker Musashi-1 modulates endometrial carcinoma cell cycle progression and apoptosis via Notch-1 and p21WAF1/CIP1. Int J Cancer. 2011;129:2042–2049. doi: 10.1002/ijc.25856. PubMed DOI
Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24:4783–4791. doi: 10.1200/JCO.2006.06.7173. PubMed DOI
Hornstein I, Alcover A, Katzav S. Vav proteins, masters of the world of cytoskeleton organization. Cell Signal. 2004;16:1–11. doi: 10.1016/S0898-6568(03)00110-4. PubMed DOI
Hubbard SA, Friel AM, Kumar B, Zhang L, Rueda BR, Gargett CE. Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res. 2009;69:8241–8248. doi: 10.1158/0008-5472.CAN-08-4808. PubMed DOI
Hunter SG, Zhuang G, Brantley-Sieders D, Swat W, Cowan CW, Chen J. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol Cell Biol. 2006;26:4830–4842. doi: 10.1128/MCB.02215-05. PubMed DOI PMC
Kitchener HC, Trimble EL, Endometrial Cancer Working Group of the Gynecologic Cancer I Endometrial cancer state of the science meeting. Int J Gynecol Cancer. 2009;19:134–140. doi: 10.1111/IGC.0b013e3181995f90. PubMed DOI
Kusunoki S, et al. The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells. Gynecologic Oncol. 2013;129:598–605. doi: 10.1016/j.ygyno.2013.03.005. PubMed DOI
Lee K, Liu Y, Mo JQ, Zhang J, Dong Z, Lu S. Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BMC Cancer. 2008;8:158. doi: 10.1186/1471-2407-8-158. PubMed DOI PMC
Lin KT, Gong J, Li CF, Jang TH, Chen WL, Chen HJ, Wang LH. Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence. Cancer Res. 2012;72:3000–3009. doi: 10.1158/0008-5472.CAN-11-2502. PubMed DOI
Liu Y, et al. Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Res. 2008;68:6396–6406. doi: 10.1158/0008-5472.CAN-08-0645. PubMed DOI PMC
Masuda H, Maruyama T, Gargett CE, Miyazaki K, Matsuzaki Y, Okano H, Tanaka M. Endometrial side population cells: potential adult stem/progenitor cells in endometrium. Biol Reprod. 2015;93:84. doi: 10.1095/biolreprod.115.131490. PubMed DOI
Matthai C, et al. Oct-4 expression in human endometrium. Mol Hum Reprod. 2006;12:7–10. doi: 10.1093/molehr/gah254. PubMed DOI
Movilla N, Bustelo XR. Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol Cell Biol. 1999;19:7870–7885. doi: 10.1128/MCB.19.11.7870. PubMed DOI PMC
Notaro S, et al. Evaluating L1CAM expression in human endometrial cancer using qRT -PCR Oncotarget. 2016;7:40221–40232. doi: 10.18632/oncotarget.9574. PubMed DOI PMC
Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment CA: a cancer. J Clin. 1999;49:297–320. PubMed
Rao S, Lyons LS, Fahrenholtz CD, Wu F, Farooq A, Balkan W, Burnstein KL. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene. 2012;31:716–727. doi: 10.1038/onc.2011.273. PubMed DOI PMC
Reimer D, et al. Clinical relevance of E2F family members in ovarian cancer—an evaluation in a training set of 77 patients. Clin Cancer Res. 2007;13:144–151. doi: 10.1158/1078-0432.CCR-06-0780. PubMed DOI
Reimer D, et al. Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response. Int J Cancer. 2017 doi: 10.1002/ijc.31186. PubMed DOI
Rutella S, et al. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res. 2009;15:4299–4311. doi: 10.1158/1078-0432.CCR-08-1883. PubMed DOI
Setiawan VW, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31:2607–2618. doi: 10.1200/JCO.2012.48.2596. PubMed DOI PMC
Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/− mice. Cancer Res. 2000;60:3605–3611. PubMed
Trenkle T, McClelland M, Adlkofer K, Welsh J. Major transcript variants of VAV3, a new member of the VAV family of guanine nucleotide exchange factors. Gene. 2000;245:139–149. doi: 10.1016/S0378-1119(00)00026-3. PubMed DOI
van der Zee M, et al. IL6/JAK1/STAT3 signaling blockade in endometrial cancer affects the ALDHhi/CD126 + stem-like component and reduces tumor. Burden Cancer Res. 2015;75:3608–3622. doi: 10.1158/0008-5472.CAN-14-2498. PubMed DOI
Verdi J, Tan A, Shoae-Hassani A, Seifalian AM. Endometrial stem cells in regenerative medicine. J Biol Eng. 2014;8:20. doi: 10.1186/1754-1611-8-20. PubMed DOI PMC
Werner HM, et al. Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. Gynecol Oncol. 2012;125:103–108. doi: 10.1016/j.ygyno.2011.11.008. PubMed DOI
Zeimet AG, et al. Ovarian cancer stem cells. Neoplasma. 2012;59:747–755. doi: 10.4149/neo_2012_094. PubMed DOI
Zeimet AG, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst. 2013;105:1142–1150. doi: 10.1093/jnci/djt144. PubMed DOI
Zeng L, et al. Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol. 2000;20:9212–9224. doi: 10.1128/MCB.20.24.9212-9224.2000. PubMed DOI PMC
